Feb 25, 2026 02:00AM
Feb 19, 2026 12:37PM
Feb 19, 2026 12:36PM
Jan 6, 2026 07:00AM
Dec 18, 2025 02:00AM
Dec 18, 2025 02:00AM
Dec 8, 2025 02:00AM PureTech gets FDA feedback supporting phase 3 trial for lung drug
Dec 8, 2025 02:00AM
Dec 5, 2025 01:00PM
Dec 5, 2025 01:00PM
Nov 3, 2025 11:37AM
Nov 3, 2025 09:00AM
Oct 22, 2025 04:44AM
Oct 22, 2025 02:00AM PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
Sep 29, 2025 02:00AM
Sep 11, 2025 07:05AM
Sep 11, 2025 07:05AM
Aug 28, 2025 02:00AM
Aug 21, 2025 07:01AM
Aug 21, 2025 07:00AM
Aug 18, 2025 02:00AM PureTech Health: Notice of Half-Yearly Results
Aug 13, 2025 12:16PM
Aug 13, 2025 12:16PM
Aug 13, 2025 12:16PM
Aug 12, 2025 07:01AM
Aug 12, 2025 07:00AM
Jul 17, 2025 07:05AM
Jul 17, 2025 07:05AM PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
Jul 16, 2025 02:00AM
Jul 8, 2025 12:45PM
Jul 8, 2025 12:45PM
Jun 26, 2025 02:00AM
Jun 16, 2025 12:59PM
May 22, 2025 07:00AM
May 20, 2025 05:15PM PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
May 9, 2025 07:00AM
May 1, 2025 07:00AM
Apr 30, 2025 02:00AM
Apr 23, 2025 02:00AM
Apr 9, 2025 02:00AM
Mar 11, 2025 07:06AM
Mar 11, 2025 07:05AM PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
Feb 25, 2025 07:27AM
Feb 12, 2025 07:05AM
Feb 12, 2025 07:05AM
Jan 27, 2025 02:00AM
Jan 9, 2025 07:00AM
Jan 8, 2025 07:00AM
Jan 6, 2025 02:00AM PureTech Appoints UBS as UK Corporate Broker
Dec 16, 2024 02:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All